Key result
National survey tracks preventive aspirin use trends across low, high, and established ASCVD risk groups.
Why the study?
To examine national trends in preventive aspirin use among populations at low and high ASCVD risk and with existing ASCVD.
Following updated 2019 guidelines, primary prevention aspirin use significantly decreased among US adults, including those for whom it is no longer recommended, though many patients with limited likelihood of benefit continue to take it.
Answers are grounded in this paper and cite their sources.
Continued aspirin use despite 2019 updates should prompt clinician review; leaves open questions on barriers to guideline implementation.
This study uses National Health and Nutrition Examination Survey data to examine national trends in preventive aspirin use among populations at low and high atherosclerotic cardiovascular disease (ASCVD) risk and with existing ASCVD.
No takes yet. Share an insight, caveat, or question.
Wilson et al. (2025) studied this question. Preventive aspirin use trends were examined among populations with low, high, and existing atherosclerotic cardiovascular disease risk using national survey data.
Synapse has enriched 10 related papers. Consider them for comparative context: